Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring

Li, Wen; Liu, Ji‐Bin; Hou, Likun; Yu, Fei; Zhang, Jie; Wu, Wei; Tang, Xiaomei; Feng, Sun; Lu, Haimin; Deng, Jing; Bai, Jie; Li, Juan; Wu, Chunyan; Lin, Qinlu; Lv, Zhongwei; Gaoren, Wang; Jiang, Gengxi; Ma, Yu‐Shui; Fu, Da

doi:10.1186/s12943-022-01505-z

Cited by 203 publications

(131 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, cell-free DNA extracted from the plasma of 234 patients with extracerebral tumors led to the detection in 76% of actionable alterations also found in tumor tissue, further strengthening LB for molecular profiling as a reliable alternative to tumor tissue biopsy. In adults, recently, analysis of cell-free DNA extracted from the blood is a recognized tool in non-small-cell lung cancer international practice guidelines [ 26 ], mostly for disease monitoring, and provides several advantages compared to analysis performed via tissue biopsy [ 27 ]. A recent study by Gouton et al was the first to evaluate the feasibility and clinical impact of liquid biopsy for cell-free DNA-based NGS analysis in pan-cancer patients, also using F1LCDx [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Blood-Derived Liquid Biopsies Using Foundation One® Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience

Cahn

Revon‐Rivière

Min

et al. 2022

Cancers

View full text Add to dashboard Cite

Precision oncology requires tumor molecular profiling to identify actionable targets. Tumor biopsies are considered as the gold standard, but their indications are limited by the burden of procedures in children. Blood-derived liquid biopsy (LB) is a potential alternative that is not yet documented in real-world settings, especially in pediatric oncology. We performed a retrospective analysis of children and teenagers with a relapsing or refractory disease, upon whom LB was performed using the Foundation One® liquid CDx from 1 January 2020 to 31 December 2021 in a single center. Forty-five patients (27 boys) were included, with a median age of 9 years of age (range: 1.5–17 years old). Underlying malignancies were neuroblastoma (12 patients), bone sarcoma (12), soft tissue sarcoma (9), brain tumors (7), and miscellaneous tumors (5). Forty-three patients had metastatic disease. Six patients had more than one biopsy because of a failure in first LB. Median time to obtain results was 13 days. Overall, analysis was successful for 33/45 patients. Eight patients did not present any molecular abnormalities. Molecular alterations were identified in 25 samples with a mean of 2.1 alterations per sample. The most common alterations concerned TP53 (7 pts), EWS-FLI1 (5), ALK (3), MYC (3), and CREBBP (2). TMB was low in all cases. Six patients received treatment based on the results from LB analysis and all were treated off-trial. Three additional patients were included in early phase clinical trials. Mean duration of treatment was 85 days, with one patient with stable disease after eight months. Molecular profiling using Foundation One® Liquid CDx was feasible in pediatric patients with high-risk solid tumors and lead to identification of targetable mutations in a subset of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Blood-Derived Liquid Biopsies Using Foundation One® Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience

Cahn

Revon‐Rivière

Min

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In liquid biopsy, the sample used is the peripheral blood of the NSCLC patients, and the common testing indicators are circulating tumor DNA (ctDNA), circulating tumor cells (CTCS), and exosomes ( 96 ). In addition, it could also detect miRNA, circRNAs, circulating tumor vascular endothelial cells (CTECs), and tumor-educated blood platelets (TEPs) ( 97 ). Compared with tissue biopsy, liquid biopsy is more sensitive, effective, practical, and acceptable, and it could provide different mutations in the tumor ( 98 ).…”

Section: The Biological Features Of Lung Cancermentioning

confidence: 99%

Current treatments for non-small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Despite improved methods of diagnosis and the development of different treatments, mortality from lung cancer remains surprisingly high. Non-small cell lung cancer (NSCLC) accounts for the large majority of lung cancer cases. Therefore, it is important to review current methods of diagnosis and treatments of NSCLC in the clinic and preclinic. In this review, we describe, as a guide for clinicians, current diagnostic methods and therapies (such as chemotherapy, chemoradiotherapy, targeted therapy, antiangiogenic therapy, immunotherapy, and combination therapy) for NSCLC.

show abstract

“…Due to their high stability and wide distribution, the significance of circRNAs as diagnostic markers in lung cancer has been evaluated. Exosomes, which contain proteins, RNAs and other components, are widely distributed in blood, saliva, milk and urine ( 35 ). Exosome-derived circRNAs have attracted widespread attention as potential diagnostic markers ( 36 ).…”

Section: Diagnostic Significance Of Circrnas In Lung Cancermentioning

confidence: 99%

Role of circular RNAs in the diagnosis, regulation of drug resistance and prognosis of lung cancer (Review)

Sang

Rao

et al. 2022

Oncol Lett

View full text Add to dashboard Cite

Lung cancer is one of the most common malignant tumors in China and is the highest cause of mortality among male and female patients, both in urban and rural areas. A subset of patients with lung cancer only display chest tightness without any other obvious symptoms. This is because most symptoms do not manifest during the early stages of disease development. Consequently, most patients with lung cancer are diagnosed when the disease is in the advanced stages, when they are already unfit for surgical treatment. Furthermore, the prognosis of patients with lung cancer is poor. The 5-year survival rate of patients with stage IA lung cancer is 85%, compared with 6% in those with stage IV. This requires the development of strategies for early diagnosis, treatment and prognosis to improve the management of lung cancer. Circular RNAs (circRNAs) belong to a class of closed circular non-coding RNAs formed by reverse splicing of a precursor mRNA. These RNAs are highly stable, ubiquitously expressed, conserved, and show high specificity. CircRNAs regulate biological processes, such as the proliferation, differentiation and invasion of lung cancer cells. Therefore, they can be used as biomarkers for the early diagnosis and prognosis prediction of lung cancer, as well as novel targets for therapy design. In the present review, the biological characteristics and functions of circRNAs, as well as their application in the diagnosis, control of drug resistance and effect on the prognosis of patients with lung cancer, will be discussed. Contents1. Introduction 2. Classification and characteristics of circRNAs 3. Biological characteristics of circRNAs 4. Biological functions of circRNAs 5. Lab/experimental protocols for the detection of circRNAs 6. Diagnostic significance of circRNAs in lung cancer 7. CircRNAs and resistance to adjuvant therapy in lung cancer 8. CircRNAs and the prognosis of patients with lung cancer 9. Limitations of circRNAs as diagnostic markers for lung cancer 10. Conclusion

show abstract

Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring

Cited by 203 publications

References 85 publications

Blood-Derived Liquid Biopsies Using Foundation One® Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience

Blood-Derived Liquid Biopsies Using Foundation One® Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience

Current treatments for non-small cell lung cancer

Role of circular RNAs in the diagnosis, regulation of drug resistance and prognosis of lung cancer (Review)

Contact Info

Product

Resources

About